Pfizer and the Companies Buying Their Way InNarrow moat

Every large pharmaceutical company wants a position in the biggest new drug category in decades, and most cannot build one. Pfizer is the instructive case: it discontinued its own oral candidate, danuglipron, in April 2025 after liver enzyme elevations, and then re-entered the category by acquiring Metsera¹.

That is the pattern across the field. AstraZeneca, Regor and others have oral candidates in development, and the acquisition market for obesity assets has become expensive precisely because internal programmes keep failing. Incretin chemistry is difficult, the trials are large and long, and a tolerability problem can end a programme after hundreds of millions have been spent — as Pfizer's did.

For Lilly this is a slower threat than it appears. An acquired clinical-stage asset still needs years of trials, a manufacturing build-out of the kind described in the Manufacturing & Scale pages, and payer acceptance against two incumbents with established outcomes data. The capital arrives quickly; the competition does not.

Watch Phase 3 readouts from the acquired programmes rather than the deal announcements. A well-funded competitor with a molecule that works is a real problem in 2029; a well-funded competitor with a molecule in Phase 2 is a press release.